A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2011
12/06/2011	CA2404736C Process for producing amine derivatives
12/06/2011	CA2393464C An additive for an animal feed
12/06/2011	CA2383522C Neurotherapeutic composition and method
12/06/2011	CA2380858C Inhibitors of aspartyl protease
12/06/2011	CA2309954C Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
12/06/2011	CA2305665C A method for treating diabetes, hyperglycemia and hypoglycemia
12/06/2011	CA2304313C Composition and method for enhancing paracellular transport across cell layers
12/06/2011	CA2232563C Live vaccine carrier strains useful for high level expression of heterologous o-antigens from gram-negative pathogens and derivatives thereof for use as live vaccines
12/06/2011	CA2211039C Medicinal combination useful for in vivo exogenic transfection and expression
12/04/2011	CA2725027A1 Methods of treating platinum-resistant recurrent ovarian cancer with 4-iodo-3-nitrobenzamide in combination with an anti-metabolite and a platinum compound
12/04/2011	CA2725026A1 Methods of treating platinum-sensitive recurrent ovarian cancer with 4-iodo-3-nitrobenzamide in combination with an anti-metabolite and a platinum compound
12/01/2011	WO2011150413A1 Antiviral compounds and uses thereof
12/01/2011	WO2011150395A2 Nutrient compositions
12/01/2011	WO2011150393A2 Methods for improving maternal and fetal health
12/01/2011	WO2011150380A1 Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders
12/01/2011	WO2011150356A1 Heterocyclic compounds as janus kinase inhibitors
12/01/2011	WO2011150347A2 Non-peptide bdnf neurotrophin mimetics
12/01/2011	WO2011150338A1 Methods of treating obesity
12/01/2011	WO2011150337A1 Nutritional compositions
12/01/2011	WO2011150320A2 Activators of innate immunity
12/01/2011	WO2011150312A1 Tocotrienol compositions
12/01/2011	WO2011150300A1 Prevention of pancreatic beta cell degeneration
12/01/2011	WO2011150299A2 Treatment of myocardial infarction and vascular injury with netrin-1
12/01/2011	WO2011150288A1 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
12/01/2011	WO2011150286A2 Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
12/01/2011	WO2011150283A1 Macrocyclic compounds useful as inhibitors of histone deacetylases
12/01/2011	WO2011150243A1 Inhibitors of hcv ns5a
12/01/2011	WO2011150239A2 Piroxicam-containing matrix patches and methods for the topical treatment of acute and chronic pain and inflammation therewith
12/01/2011	WO2011150229A2 Dietary supplements containing extracts of cinnamon and methods of using same to promote enhanced sirtuin, cell and telomere integrity
12/01/2011	WO2011150198A1 Azolyl urea compounds and methods of use thereof
12/01/2011	WO2011150183A1 Radiolabeled compounds and methods thereof
12/01/2011	WO2011150162A1 Methods for treating viral conditions
12/01/2011	WO2011150160A2 Method of preventing and treating inflammatory diseases and disorders with abscisic acid
12/01/2011	WO2011150156A2 Heteroaryl compounds and methods of use thereof
12/01/2011	WO2011150102A1 Cyclosporin emulsions
12/01/2011	WO2011150094A2 Tumor suppression compositions
12/01/2011	WO2011150067A1 Treatment of blood lipid abnormalities and other conditions
12/01/2011	WO2011150044A1 Combination
12/01/2011	WO2011150030A2 Method to alleviate diabetic end stage renal disease
12/01/2011	WO2011150017A1 Use of terilfunomide for maintaining fatigue level of a patient having multiple sclerosis
12/01/2011	WO2011150016A1 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
12/01/2011	WO2011150014A1 Use of teriflunomide for treating brain atrophy
12/01/2011	WO2011150007A2 Treatment of methionine sulfoxide reductase a (msra) related diseases by inhibition of natural antisense transcript to msra
12/01/2011	WO2011150005A2 Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
12/01/2011	WO2011149995A1 Novel substituted octahydrocyclopenta [c]pyrrol-4-amines as calcium channel blockers
12/01/2011	WO2011149993A2 SUBSTITUTED OCTAHYDROCYCLOPENTA[c]PYRROLES AS CALCIUM CHANNEL MODULATORS
12/01/2011	WO2011149963A1 Substituted-6-methylnicotinamides as mglur5 positive allosteric modulators
12/01/2011	WO2011149950A2 Bicyclic heteroaryl kinase inhibitors and methods of use
12/01/2011	WO2011149937A1 Heterocyclic compounds and uses thereof
12/01/2011	WO2011149921A1 Soluble guanylate cyclase activators
12/01/2011	WO2011149881A2 Methods for the treatment and prevention of inflammatory diseases
12/01/2011	WO2011149878A1 An aminopyrazole triazolothiadiazole inhibitor of c-met protein kinase
12/01/2011	WO2011149877A2 Intestinal brake inducing intraluminal therapeutic substance eluting devices and methods
12/01/2011	WO2011149862A1 Nicotinic receptor non-competitive antagonists modulators
12/01/2011	WO2011149859A1 Nicotinic receptor non-competitive antagonists
12/01/2011	WO2011149851A1 Antimicrobial compositions
12/01/2011	WO2011149841A1 SUBSTITUTED THIAZOLIDINEDIONE INDAZOLES, INDOLES AND BENZOTRIAZOLES AS ESTROGEN-RELATED RECEPTOR-α MODULATORS
12/01/2011	WO2011149827A1 Compounds and methods
12/01/2011	WO2011149824A1 Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor
12/01/2011	WO2011149814A2 Effervescent composition for forming a gelled composition, tablet for forming a gelled composition, and method of making a gelled composition
12/01/2011	WO2011149801A1 Naphthalene carboxamide m1 receptor positive allosteric modulators
12/01/2011	WO2011149766A2 Lipid-tailored pharmaceutical agents
12/01/2011	WO2011149757A1 Coordination complexes, pharmaceutical solutions comprising coordination complexes, and methods of treating patients
12/01/2011	WO2011149645A1 Topical etoricoxib formulation
12/01/2011	WO2011149601A1 Treatment of vagally- mediated spectrum disorders with 5ht3 antagonists
12/01/2011	WO2011149595A1 Combination therapy for skin disorders
12/01/2011	WO2011149529A2 Cell-based preparations for wound management
12/01/2011	WO2011149492A1 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
12/01/2011	WO2011149471A1 Method to prevent/treat post-operative induced constipation
12/01/2011	WO2011149461A1 Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
12/01/2011	WO2011149438A1 Combination of antihypertensive agents
12/01/2011	WO2011149419A1 Vaccine against streptococcal infections based on recombinant proteins
12/01/2011	WO2011149412A1 Injectable emulsion of sedative hypnotic agent
12/01/2011	WO2011149354A1 Mirnas involved in the blood brain barrier function
12/01/2011	WO2011149349A1 2-iminobiotin formulations and uses thereof
12/01/2011	WO2011149288A2 Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases, and pharmaceutical composition containing same
12/01/2011	WO2011149250A2 Tricarbonyl technetium-99m or rhenium-188 label ring rgd derivative, a preparation method thereof, and a pharmaceutical composition containing the derivative as an active ingredient for use in the diagnosis or treatment of angiogenesis-related diseases
12/01/2011	WO2011149213A2 Novel derivative having inhibitory activity against 11β-hsd1, preparation method thereof, and pharmaceutical composition containing same as active ingredient
12/01/2011	WO2011149206A2 Pharmaceutical composition containing crystalline nebivolol hydrochloride and method for preparing the same
12/01/2011	WO2011149134A1 Anticancer composition
12/01/2011	WO2011149126A1 Pharmaceutical composition comprising an anti-inflammatory compound having a tyrosine kinase inhibiting function
12/01/2011	WO2011149110A1 Novel composition for the prevention and/or treatment of thromboembolism
12/01/2011	WO2011149099A1 Antigen peptide and use thereof
12/01/2011	WO2011149051A1 Antitumor t cell response enhancer
12/01/2011	WO2011149046A1 Therapeutic agent for pancreatic cancer
12/01/2011	WO2011149012A1 Prophylactic or therapeutic agent for retinal/choroidal denaturation diseases comprising isoquinolinesulfonyl derivative as active ingredient, prophylactic or therapeutic method for retinal/choroidal denaturation diseases, and isoquinolinesulfonyl derivative or pharmaceutically acceptable salt thereof and use thereof
12/01/2011	WO2011149011A1 Novel indazole derivative or salt thereof, manufacturing intermediate therefor, antioxidant using same, and use for an indazole derivative or salt thereof
12/01/2011	WO2011149010A1 Novel indazole derivative or salt thereof, intermediate for the production of same, prophylactic or therapeutic agent for chorioretinal denaturative diseases and therapeutic method for chorioretinal denaturative diseases each utilizing same, and use of indazole derivative or salt thereof
12/01/2011	WO2011148962A1 Novel heterocyclic compound or salt thereof
12/01/2011	WO2011148956A1 Fused imidazole derivative
12/01/2011	WO2011148922A1 Novel quinazoline compound
12/01/2011	WO2011148888A1 Heterocyclic ring compound and h1 receptor antagonist
12/01/2011	WO2011148829A1 Pet food
12/01/2011	WO2011148657A1 Composition for prevention, amelioration or treatment of metabolic syndrome
12/01/2011	WO2011148648A1 Influenza virus infection inhibitor
12/01/2011	WO2011148640A1 Blood flow promoter and external preparation
12/01/2011	WO2011148405A1 Compositions for treating helicobacter pylori infection
12/01/2011	WO2011148381A1 Salts of raltegravir
12/01/2011	WO2011148380A1 Oral pharmaceutical composition of duloxetine
12/01/2011	WO2011148247A1 Stabilized formulation comprising omega-3 fatty acids and use of the fatty acids for skin care and/or wound care

1 ... 1454 1455 1456 1457 1458 1459 1460 1461 1462 1463 1464 1465 1466 1467 1468 1469 1470 1471 1472 1473 1474 ... 7860